CUROSURF 80 MG
PORACTANT ALFA : 80 MG · DIN 02241551 · CHIESI FARMACEUTICI S.P.A.
Health Canada status: MARKETED
What is CUROSURF?
CUROSURF 80 MG contains PORACTANT ALFA : 80 MG. It is listed in the Health Canada Drug Product Database under DIN 02241551, held by CHIESI FARMACEUTICI S.P.A., supplied as SUSPENSION for INTRATRACHEAL administration. Health Canada currently lists it as marketed, status dated 19-Dec-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CUROSURF used for?
Curosurf (poractant alfa) is indicated for the treatment of Respiratory Distress Syndrome (RDS) in premature infants requiring mechanical ventilation with clinical signs of surfactant deficiency and/or RDS confirmed by x-ray. The first dose of Curosurf has to be administered as soon as possible, preferably within 6 hours of birth.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02241551 |
|---|---|
| Brand name | CUROSURF |
| Generic / active ingredient | PORACTANT ALFA : 80 MG |
| Manufacturer | CHIESI FARMACEUTICI S.P.A. |
| Strength | 80 MG |
| Dosage form | SUSPENSION |
| Route of administration | INTRATRACHEAL |
| Schedule | Prescription |
| ATC code | R07AA02 NATURAL PHOSPHOLIPIDS |
| AHFS class | 48:36.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 19-Dec-2016 |
| Original market date | 2016-12-19 00:00:00 |
How is it stored and handled?
null
How is it supplied?
Sterile, ready-to-use rubber-stoppered clear glass vials containing 1.5 mL or 3 mL. One vial per carton.
What can be used instead?
Other Canadian products sharing ATC code R07AA02 NATURAL PHOSPHOLIPIDS. 3 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BLES | 27 MG | SUSPENSION | BLES BIOCHEMICALS INC | MARKETED | DIN 02245464 |
| SURVANTA | 25 MG | SUSPENSION | ABBVIE CORPORATION | MARKETED | DIN 02016109 |
| NEOSURF | 27 MG | SUSPENSION | CIPLA LTD | CANCELLED (UNRETURNED ANNUAL) | DIN 02288621 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.